<DOC>
	<DOCNO>NCT00690573</DOCNO>
	<brief_summary>To evaluate efficacy , safety pharmacokinetics adalimumab Japanese child Polyarticular Juvenile Rheumatoid Arthritis</brief_summary>
	<brief_title>Safety , Efficacy , Pharmacokinetics Adalimumab Japanese Children With Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description>This open-label long-term study complete follow study drug approval Japan treatment JRA . Data present Week 144 final visit .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion Criteria Diagnosis polyarticular juvenile rheumatoid arthritis ( JRA ) accord criteria American College Rheumatology ( ACR ) Disease activity inadequately control nonsteroidal antiinflammatory drug ( NSAIDs ) methotrexate ( MTX ) Presence screen least 5 swollen joint ( due deformity ) least 3 joint limitation passive motion pain passive motion or/and pain pressure ( tenderness ) Stable dosage MTX least 12 week prior screen visit discontinuation MTX least 14 day prior baseline visit ( Day 1 ) Discontinuation diseasemodifying antirheumatic drug ( DMARDs ) MTX least 28 day screen visit Exclusion Criteria History inflammatory joint disease JRA Functional class IV JRA ACR criterion Clinically significant cardiac disease laboratory abnormalities Any subject consider investigator , reason , unsuitable candidate study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Juvenile Rheumatoid Arthritis</keyword>
</DOC>